Recovery and discharge time between remimazolam

- 2 tosylate and propofol in hysteroscopy anesthesia: a
- 3 randomized controlled study
- 6 Xiangyi Lin¹, Shengjie Chen¹, Huiyan Liang¹
- 8 ¹ Department of Anesthesiology, Maternal and Child Health Hospital of Shunde Foshan, Shunde
- 9 Women and Children's Hospital of Guangdong Medical University, Foshan 528300,
- 10 Guangdong, China

1

4

5

7

11

18

- 12 Corresponding Author:
- 13 Shengjie Chen ¹
- 14 Department of Anesthesiology, Maternal and Child Health Hospital of Shunde Foshan, Shunde
- Women and Children's Hospital of Guangdong Medical University, NO.3 Baojian Road Street,
- 16 Foshan, Guangdong, 528300, China
- 17 Email address: sdsilence@hotmail.com
- 19 **Abstract**
- 20 **Background.** Hysteroscopy is considered the gold standard for the evaluation and treatment of
- 21 uterine and endometrial lesions, but the operation is accompanied by severe pain, so it needs to
- be performed under anesthesia. Currently, a new sedative drug, remimazolam tosilate, can be

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

used in digestive endoscopy and bronchoscopy. We will study its effect on hysteroscopy and its impact on patient recovery time and hospital discharge time. **Methods.** Ninety-five patients undergoing hysteroscopy were randomly divided into two groups and received an initial dose of 0.2 mg/kg remimazolam tosilate (R group) and an initial dose of 2 mg/kg propofol (P group) as anesthetics during the examination. The primary end point was anesthesia recovery time (the time required for the patient's MOAA/S score to reach 5 from the cessation of drug use) and hospital discharge time (the time required for the patient's PADS score to reach 9 from the cessation of drug use). Secondary endpoints were first-dose sedation success rate, incidence of hypotension, and injection pain. **Results.** Age(P = 0.825), height(P = 0.174), weight(P = 0.667) and ASA grade (P = 0.972) were not significantly different between the two groups. The recovery time in the R group was significantly shorter than that in the P group (P = 0.019), and the data kurtosis in the R group was higher than that in the P group (1.19 vs -0.56), but there was no significant difference in the time to hospital discharge (P = 0.696). There was no significant difference in the success rate of the first dose of sedation between the two groups (P = 0.362), but the incidence of hypotension during anesthesia (P = 0.001) and the incidence of injection pain (P = 0.001) in the R group was significantly lower than those in P group. **Conclusions.** Remimazolam tosilate is suitable for hysteroscopy anesthesia and can reduce intraoperative hypotension and injection pain during the examination, a more optimal dosage or target-controlled infusion model still needs to be further explored. Introduction Hysteroscopy is considered to be the gold standard for evaluating and managing uterine and endometrial lesions (van Hanegem et al. 2016; Wang et al. 2021), but cervical dilation and endometrial curettage are accompanied by severe pain(Riemma et al. 2020). Therefore, most hysteroscopies are performed under anesthesia. The most commonly used sedative drug is

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

propofol due to its fast effect(Yu et al. 2019), easy titration, and short half-life, and can also reduce postoperative nausea and vomiting(Schraag et al. 2018). But its large impact on hemodynamics, no specific antagonists, and accumulation after long-term infusion have been its significant adverse effects in clinical application. As a novel ultra-short-acting benzodiazepine sedative drug, remimazolam tosilate has been successfully used as a sedative in bronchoscopy(Jia et al. 2021) and gastrointestinal endoscopy(Rex et al. 2018). It is designed to be rapidly hydrolyzed in the body by ubiquitous tissue esterases to an inactive carboxylic acid metabolite(Kilpatrick et al. 2007). Compared with the existing benzodiazepines, it has a faster onset of action, a shorter and predictable duration of sedation, and outstanding advantages in short-term anesthesia and operation. This study hopes to provide patients with more comfort and shorten treatment time by analyze and comparing the differences in recovery time, hospital discharge time and injection pain indicators between remimazolam tosilate and propofol in anesthesia for hysteroscopy. **Materials & Methods Study Design and Participants** This study is a single-center, parallel randomized controlled study, which was approved by the Medical Research Ethics Committee of Shunde Women and Children's Hospital of Guangdong Medical University (Maternal and Child Health Hospital of Shunde Foshan) (registration number:2020055) and registered on Chictr.org (Date of Registration:15/07/2021, Registration number:ChiCTR2100048738). The study protocol followed the CONSORT and related clinical guidelines. All patients participating in the study signed written informed consent of participation and publication. Inclusion criteria for this study: 1. planning to undergo hysteroscopy without endotracheal intubation; 2. aged 18-50 years; 3. American Society of Anesthesiologists (ASA) Physical Status rating I-II. Exclusion criteria: 1. Underweight or overweight (BMI>=30 or <18.5); 2. Anemia

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

(HGB≤90g/L); 3. Severe liver and kidney dysfunction; 4. History of sedative abuse and mental illness; 5. Pregnancy or Within 3 months of breastfeeding; 6. Those who intend to undergo spinal anesthesia during examination and operation and those who refuse to participate in this study. Randomization and Blinding In this study, the block randomization method was adopted, and R software was used to generate a random sequence based on 4 patients as a block, and the allocation ratio is 1:1. The results were put into opaque envelopes. After the patients signed the informed consent, the researchers unsealed the corresponding envelopes, and allocated the patients. Enter the remimazolam group (R group) and propofol group (P). The study was blinded to the follow-up staff. Research intervention All patients received intravenous anesthesia, and patient monitor (iPM8, Mindray Biomedical Electronics Co., Ltd., Shenzhen, China) was used to measure non-invasive blood pressure, SpO2, ECG and RESP during anesthesia and recovery. After monitoring and venous catheter placement, the initial dose of remimazolam tosilate (Jiangsu Hengrui Pharmaceutical Co., Ltd., China) in R group was 0.2 mg/kg, followed by infusion at a rate of 1 mg/kg*hr, and an additional 0.1 mg/kg remimazolam was given for body movement during the examination The rescue dose was given no more than once every 5 minutes; the initial dose of propofol (Zhejiang Nhwa Pharmaceutical Co., Ltd., China) in P group was 2 mg/kg, followed by infusion at a rate of 8 mg/kg*hr, and an additional 1 mg/kg propofol was given to those who experienced body movement during the examination. The rescue dose was given no more than once every 5 minutes. At the end of the examination, flurbiprofen axetil (Grand Life Sciences(Wuhan) Co., Ltd., China) 50 mg was administered intravenously for postoperative analgesia. Sample size and statistical analysis

In a pilot study of hysteroscopy using propofol and remimazolam(Zhang et al. 2021), patients spent 5.44 minutes (remimazolam group) and 6.3 minutes (propofol group) in the PACU, with a standard deviation of 1.45. A sample size of 45 participants per group was calculated with a significance level of 0.05 (a = 0.05), a strength of 80% (b = 0.20), and a dropout rate of 10%. Statistical analysis was performed using SPSS Statistics 25.0 (SPSS Inc., Chicago, IL). Normality test in SPSS statistics software was used for data analysis to determine whether the data were in accordance with a normal distribution. Normally distributed continuous variables are presented as the mean ± standard deviation and were analyzed using Student's t test. The Mann-Whitney U test was used for non-normally distributed continuous variables. Categorical variables are expressed as a frequency (percentage) and were analyzed using the Pearson chisquare test. The Wilcoxon Signed-Rank test was used to compare continuous variables. A p value < 0.05 was considered to indicate statistical significance.

Data Measurement and Acquisition

Demographic data including age, height, weight, and American Society of Anesthesiologists (ASA) rating were recorded for all cases. The main endpoints of the study were the patient's recovery time from anesthesia (the time required for the subject's MOAA/S(Chernik et al. 1990) score to be 5 points since stopping the use of remimazolam or propofol) and the time to hospital discharge (the time required for the subject's PADS(Palumbo et al. 2013) score to express 9 points since stopping the use of remimazolam or propofol). The secondary endpoints were the success of the first dose of sedation (1 minute after the administration of the initial dose of the drug, the eyelashes of the patient were stimulated with a cotton swab, and the sedation was considered successful if there was no reflex), the occurrence of hypotension (the blood pressure during anesthesia decreased by more than 20% compared with the systolic blood pressure during the fully awake period or the systolic blood pressure decreased by more than 20%. If the systolic blood pressure drops to ≤80mmHg, hypotension is considered to be present) and injection pain occurs (when the initial dose of drug is given, involuntary retraction of the limb on

the injection side or the patient complains of pain in the limb on the injection side is considered to be pain).

Results

From July 28, 2021 to September 2, 2021, a total of 155 patients were included in this study, and 14 cases were excluded due to reasons such as high or low BMI, anemia, patients receiving assisted reproductive technology or breastfeeding. 46 cases were excluded and withdrawn due to patients or family members refusing to participate in the study or incomplete relevant information. A total of 95 patients were finally analyzed in this study (Fig.1). Demographic data are detailed in Table 1, age (P = 0.825), height (P = 0.174), weight(P = 0.667) and ASA grade(P = 0.972) were not significantly different between the two groups.

Figure 1:Flow Diagram

Table1:

Demographic data (N = 95).

137 All data are expressed as means \pm SD.

	Groups				Significance	Cohen's
Parameters	Remimazolam	Propofol	t/ χ ² Value	Df	(<i>P</i>)	d/
	(n=48)	(n=47)				Phi
Age (year)	32.56±6.687	32.26±6.829	0.222	93	0.83	0.044
Height (cm)	157.10±3.910	158.23±4.124	-1.371	93	0.17	-0.281
Weight	55.98±5.208	56.45±5.340	-0.432	93	0.67	-0.089
(Kg)						
ASA I/II (n	40/5	40/5	0.001	1	0.07	0.005
)	43/5	42/5			0.97	

As for the primary endpoint, the recovery time from anesthesia in group R was significantly shorter than that in group P (P = 0.019), and the data kurtosis in group R was higher than that in

group P(1.19 vs -0.56), but there was no significant difference in the time to hospital discharge (P = 0.696).In secondary endpoints, there was no significant difference in the success rate of the first dose of sedation between the two groups (P = 0.362), but the incidence of hypotension during anesthesia (P=0.001) and the incidence of injection pain (P = 0.001) in group R were significantly lower than those in group R. (Table 2)

Table2:

Measurement data (N = 95).

All data are expressed as means ± SD.

	Groups	t/ x ²		Significa	Cohen's d/	
Parameters	Remimazola	Propofol		Df	nce	
	m(n=48)	(n=47)	Value		(P)	Phi
Anesthesia	6.23±1.547	7.09±1.932	-2.386	93	0.019	-0.491
recovery time(min)	0.23±1.347	7.0911.932	-2.300	93	0.019	-0.491
Discharge	89.58±18.66	91.23±22.23	-0.392	93	0.696	-0.804
time(min)	9	5	-0.532	90	0.090	-0.004
First dose sedation	44(04.70/)	46(07.00/)	1.834	1	0.362	0.601
success(n)	44(91.7%)	46(97.9%)	1.034	1	0.302	0.001
Hypotension(n)	10(20.8%)	26(55.3%)	12	1	0.001	3.364
Injection pain(n)	6(12.5%)	32(68.1%)	30.572	1	0.001	5.529

Discussion

Through this study, it can be found that remimazolam tosilate is used as the initial dose of 0.2 mg/kg in hysteroscopy anesthesia, which has a sedative success rate not inferior to that of propofol, and the average recovery time is shorter and more concentrated. Suggesting that when it is used for hysteroscopic anesthesia, patients need to stay in the PACU for a shorter time, and the drug metabolism is more predictable, which is beneficial to reduce the burden on

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

PACU doctors and nurses and improve turnaround efficiency. The lower incidence of intraoperative hypotension in patients taking concomitant remimazolam tosilate may be a potential benefit of remimazolam, because intraoperative hypotension caused by anesthetic drugs has been shown to be associated with various postoperative organ dysfunction and adverse outcomes (Wesselink et al. 2018). In addition, the less incidence of injection pain may give remimazolam tosilate an advantage in special patients (eg. children)(Nyman et al. 2005). This study did not find that remimazolam tosilate was associated with the shortening of hospital discharge time, which may be due to the limitations of the design of this study, for example, this study was a single-center study with a small sample size, and no propensity scoring or weighted statistics were performed on patients' preoperative fasting time or individual nutritional status. **Conclusions** Remimazolam tosilate is suitable for hysteroscopy anesthesia. Remimazolam tosilate can reduce intraoperative hypotension and injection pain during examination sedation. Recovery time may be further shortened with specific antagonist flumazenil. More optimal dosage or target-controlled infusion model still needs to be further explored. **Acknowledgements** The author thanks the anesthetist nurses for their dedication to patient observation and data collection **Declarations** The data that supports the findings of this study are available within supplementary material. No potential competing interest was reported by the authors. The authors received no financial support for the research, authorship, or publication of this article.

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

Xiangyi Lin and Shengjie Chen wrote the main manuscript text, Huiyan Liang collected and counted all the clinical data, all authors reviewed the manuscript. References Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam EM, and Siegel JL. 1990. Validity and Reliability of the Observer's: Assessment of Alertness/Sedation Scale: Study with: Intravenous Midazolam. Journal of Clinical Psychopharmacology 10. Jia Z, Ren LX, Fan YT, and Tan ZM. 2021. [Observation of effective dosage of remimazolam. tosilate used for moderate-to-deep sedation in fiberoptic bronchoscopy]. Zhonghua yi xue za zhi 101:813-816. 10.3760/cma.j.cn112137-20200901-02524 Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, Wiard RP, Feldman PL, Collins H, Waszczak BL, and Tilbrook GS. 2007. CNS 7056: A Novel Ultra-shortacting Benzodiazepine. Anesthesiology 107:60-66. 10.1097/01.anes.0000267503.85085.c0 Nyman Y, von Hofsten K, Georgiadi A, Eksborg S, and Lönngvist PA. 2005. Propofol injection pain in children: a prospective randomized double-blind trial of a new propofol formulation versus propofol with added lidocaine. BJA: British Journal of Anaesthesia 95:222-225. 10.1093/bja/aei156 Palumbo P, Tellan G, Perotti B, Pacilè MA, Vietri F, and Illuminati G. 2013. Modified PADSS (Post Anaesthetic Discharge Scoring System) for monitoring outpatients discharge. Ann Ital Chir 84:661-665. Rex DK, Bhandari R, Desta T, DeMicco MP, Schaeffer C, Etzkorn K, Barish CF, Pruitt R, Cash BD, Quirk D, Tiongco F, Sullivan S, and Bernstein D. 2018. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointestinal Endoscopy 88:427-437.e426. https://doi.org/10.1016/j.gie.2018.04.2351

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

Riemma G, Schiattarella A, Colacurci N, Vitale SG, Cianci S, Cianci A, and De Franciscis P. 2020. Pharmacological and non-pharmacological pain relief for office hysteroscopy: an up-to-date review. Climacteric 23:376-383. 10.1080/13697137.2020.1754388 Schraag S, Pradelli L, Alsaleh AJO, Bellone M, Ghetti G, Chung TL, Westphal M, and Rehberg S. 2018. Propofol vs. inhalational agents to maintain general anaesthesia in ambulatory and in-patient surgery: a systematic review and meta-analysis. BMC Anesthesiology 18:162. 10.1186/s12871-018-0632-3 van Hanegem N, Prins MMC, Bongers MY, Opmeer BC, Sahota DS, Mol BWJ, and Timmermans A. 2016. The accuracy of endometrial sampling in women with postmenopausal bleeding: a systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology 197:147-155. https://doi.org/10.1016/j.ejogrb.2015.12.008 Wang C, Feng Y, Zhou W-J, Cheng Z-J, Jiang M-Y, Zhou Y, and Fei X-Y. 2021. Screening and identification of endometrial proteins as novel potential biomarkers for repeated implantation failure. *PeerJ* 9:e11009. 10.7717/peerj.11009 Wesselink EM, Kappen TH, Torn HM, Slooter AJC, and van Klei WA. 2018. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. British Journal of Anaesthesia 121:706-721. https://doi.org/10.1016/j.bja.2018.04.036 Yu J, Xiang B, Song Y, Chen H, Li Y, and Liu C. 2019. ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. Basic & Clinical Pharmacology & Toxicology 125:460-465. https://doi.org/10.1111/bcpt.13280 Zhang X, Li S, and Liu J. 2021. Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial. BMC Anesthesiology 21:156. 10.1186/s12871-021-01373-y




Figure1